SAN DIEGO, Jan. 30, 2017 /PRNewswire/ — Medical Marijuana, Inc. (OTC PINK:MJNA), the first publicly traded cannabis company in the United States, today announced that its subsidiary HempMeds® Mexico has launched its new website, featuring a fresh interface, educational info, and online services for medical marijuana customers.
HempMeds® Mexico`s non-psychoactive, hemp-based CBD product Real Scientific Hemp Oil-X™ (RSHO-X™) was the first-ever federally approved CBD product in Mexico.
“We are very pleased to provide a superior customer experience with the launch of the new HempMeds® Mexico website,” said Medical Marijuana, Inc. CEO, Dr. Stuart Titus. “In addition to the new design, imagery and messaging capabilities, the site’s true value will come from the educational content – from customer stories, to research studies and product development.”
Dr. Titus added, “This launch is another step towards our goal of continuing to work with government officials to provide customers with safe, legal access to CBD hemp oil products.”
The new site displays pertinent information and extended convenience for current customers, and for those looking to obtain medical consultations. Potential consumers can now receive online treatment consultations, as well as assistance through the program’s legal authorization process. Established patients will also gain access to prescription delivery services, industry updates, treatment options and product details. Customers can also use HempMeds® Mexico`s live support call in numbers for any additional questions or needs – From Mexico Call: 001-883-786-2440; From The U.S. Call: 1-866-786-2440.
About HempMeds® Mexico
HempMeds®Mexico is a Mexico-based company that made history by being the first company to receive a COFEPRIS federal government import permit for the cannabis product RSHO-X™ for a medical indication. HempMeds® Mexico plans to work directly with the Mexican government to safely and legally provide access to CBD hemp oil products. For more information, please review the company’s website at: http://www.hempmeds.mx.
About Medical Marijuana, Inc.
Our mission is to be the premier cannabis and hemp industry innovators, leveraging our team of professionals to source, evaluate and purchase value-added companies and products, while allowing them to keep their integrity and entrepreneurial spirit. We strive to create awareness within our industry, develop environmentally-friendly, economically sustainable businesses, while increasing shareholder value. For details on Medical Marijuana, Inc.’s portfolio and investment companies, visit www.medicalmarijuanainc.com.
To see Medical Marijuana, Inc.’s video statement, click here. Shareholders are also encouraged to visit the Medical Marijuana, Inc. Shop for discounted products.
This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of Medical Marijuana, Inc. to be materially different from the statements made herein.
FOOD AND DRUG ADMINISTRATION (FDA) DISCLOSURE
These statements have not been evaluated by the FDA and are not intended to diagnose, treat or cure any disease.
Medical Marijuana, Inc. does not sell or distribute any products that are in violation of the United States Controlled Substances Act (US.CSA). These companies do grow, sell, and distribute hemp-based products and are involved with the federally legal distribution of medical marijuana-based products within certain international markets. Cannabidiol is a natural constituent of hemp oil.
Public Relations Contact:
Chief Executive Officer
P. 888-829- 0070
Investor Relations Contact:
Toll Free: (877) 964.6463
Office/Direct: (858) 264-6500
Email: [email protected]